Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Trial Profile

A Retro-Prospective Observational Study of Ibrutinib Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Ibrutinib (Primary)
  • Indications Chronic lymphocytic leukaemia; Mantle-cell lymphoma
  • Focus Therapeutic Use
  • Acronyms FIRE
  • Sponsors Janssen-Cilag
  • Most Recent Events

    • 08 Nov 2018 Planned number of patients changed from 500 to 600.
    • 08 Nov 2018 Planned End Date changed from 22 May 2024 to 22 May 2022.
    • 28 Jun 2018 Planned End Date changed from 22 May 2022 to 22 May 2024.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top